Diametric Capital LP Acquires Shares of 26,224 Caribou Biosciences, Inc. (NASDAQ:CRBU)

Diametric Capital LP bought a new position in Caribou Biosciences, Inc. (NASDAQ:CRBU) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 26,224 shares of the company’s stock, valued at approximately $42,000.

A number of other institutional investors have also made changes to their positions in CRBU. Erste Asset Management GmbH acquired a new position in Caribou Biosciences in the third quarter worth $28,000. US Bancorp DE boosted its holdings in shares of Caribou Biosciences by 3,524.2% in the 4th quarter. US Bancorp DE now owns 27,218 shares of the company’s stock valued at $43,000 after buying an additional 26,467 shares during the period. Intech Investment Management LLC bought a new stake in shares of Caribou Biosciences during the 3rd quarter valued at about $43,000. Thrive Wealth Management LLC acquired a new stake in Caribou Biosciences during the fourth quarter worth about $51,000. Finally, Sei Investments Co. bought a new position in Caribou Biosciences in the fourth quarter worth about $102,000. 77.51% of the stock is currently owned by institutional investors.

Caribou Biosciences Price Performance

CRBU opened at $0.86 on Thursday. The company has a market capitalization of $80.08 million, a PE ratio of -0.52 and a beta of 2.34. The business has a 50-day moving average of $1.19 and a 200-day moving average of $1.68. Caribou Biosciences, Inc. has a fifty-two week low of $0.72 and a fifty-two week high of $4.92.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings data on Monday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The firm had revenue of $2.08 million during the quarter, compared to analysts’ expectations of $2.11 million. On average, equities research analysts expect that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on CRBU. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Caribou Biosciences in a report on Wednesday, March 19th. Bank of America cut their target price on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $10.33.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.